Why Is Zoetis (ZTS) Up 1.4% Since Last Earnings Report?

Zacks09-05

It has been about a month since the last earnings report for Zoetis (ZTS). Shares have added about 1.4% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2465834520?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0K2vxHTAGj_tGrBqjPJ8Cg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f889276f4a638f3c7a79c0e3e6b768c1","is_english":true,"pubTime":"2024-09-05 23:31","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2465834520","market":"us","top_or_hot":-1,"title":"Why Is Zoetis (ZTS) Up 1.4% Since Last Earnings Report?","media":"Zacks","content":"<div>\n<p>It has been about a month since the last earnings report for Zoetis (ZTS). Shares have added about 1.4% in that time frame, underperforming the S&P 500.\nWill the recent positive trend continue leading...</p>\n\n<a href=\"https://finance.yahoo.com/news/why-zoetis-zts-1-4-153121153.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Zoetis (ZTS) Up 1.4% Since Last Earnings Report?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Zoetis (ZTS) Up 1.4% Since Last Earnings Report?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-05 23:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/why-zoetis-zts-1-4-153121153.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It has been about a month since the last earnings report for Zoetis (ZTS). Shares have added about 1.4% in that time frame, underperforming the S&P 500.\nWill the recent positive trend continue leading...</p>\n\n<a href=\"https://finance.yahoo.com/news/why-zoetis-zts-1-4-153121153.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://finance.yahoo.com/news/why-zoetis-zts-1-4-153121153.html","article_id":"2465834520","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0K2vxHTAGj_tGrBqjPJ8Cg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f889276f4a638f3c7a79c0e3e6b768c1"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2465834520","pubTimestamp":1725550281,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"It has been about a month since the last earnings report for Zoetis . Shares have added about 1.4% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Zoetis due for a pullback?Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.Zoetis Q2 Earnings & Revenues Beat, ’24 Outlook Raised. Zoetisdelivered second-quarter 2024 adjusted earnings  of $1.56 per share, which surpassed the Zacks Consensus Estimate of $1.49. In the year-ago quarter, the company delivered adjusted earnings of $1.41 per share.Sales of companion animal products rose 7% on a reported basis and 12% on an operational basis, driven by growth in several key products. These included OA pain products, Librela for dogs and Solensiafor cats, dermatology products like Apoquel and Cytopoint, as well as Zoetis’ para","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"为什么硕腾(ZTS)自上次收益报告以来上涨了1.4%？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZTS":1,"IONS":0.9},"content_text":"It has been about a month since the last earnings report for Zoetis (ZTS). Shares have added about 1.4% in that time frame, underperforming the S&P 500.\nWill the recent positive trend continue leading up to its next earnings release, or is Zoetis due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. \nZoetis Q2 Earnings & Revenues Beat, ’24 Outlook Raised\nZoetisdelivered second-quarter 2024 adjusted earnings (excluding one-time items) of $1.56 per share, which surpassed the Zacks Consensus Estimate of $1.49. In the year-ago quarter, the company delivered adjusted earnings of $1.41 per share.\nTotal revenues grew 8% year over year to $2.36 billion in the reported quarter, which also beat the Zacks Consensus Estimate of $2.30 billion. In the year-ago quarter, the company reported total revenues of $2.18 billion.\nQuarterly Highlights\nZoetis derives the majority of its revenues from a diversified product portfolio of medicines and vaccines used to treat and protect livestock and companion animals. The company reports business results under two geographical operating segments — the United States and International.\nRevenues from the U.S. segment increased 12% year over year to $1.31 billion in the reported quarter, beating both the Zacks Consensus Estimate as well as our model estimate of $1.26 billion.\nSales of companion animal products in the U.S. region jumped 13% from the prior-year quarter’s level to $1.08 billion, driven by Zoetis’ monoclonal antibody products for osteoarthritis (OA) pain, Librela for dogs and Solensiafor cats, as well as its flea, tick and heartworm combination product for dogs, Simparica Trio. The uptick was also fueled by the company’s key dermatology portfolio, including Apoqueland Cytopoint.\nSales of livestock products in the United States increased 11% in the second quarter to $228 million, mainly driven by higher sales ofcattle and swine products due to favorable timing of supply of ceftiofur compared with the year-ago quarter.\nRevenues in the International segment improved 4% year over year on a reported basis and 10% on an operational basis to $1.04 billion, beating both the Zacks Consensus Estimate and our model estimate of $1.02 billion.\nSales of companion animal products rose 7% on a reported basis and 12% on an operational basis, driven by growth in several key products. These included OA pain products, Librela for dogs and Solensia for cats, dermatology products like Apoquel and Cytopoint, as well as Zoetis’ parasiticide products, such as Simparica and the Simparica Trio.\nOn a year-over-year basis, livestock product sales were flat on a reported basis but grew 8% operationally. Growth in both the cattle and poultry portfolios was driven largely by price increases across the broader international segment. Additionally, sales of fish products grew due to increased demand for vaccines in Norway.\n2024 Guidance Raised\nZoetis now expects adjusted earnings in the range of $5.78-$5.88 per share in 2024 compared with the previous guidance of 5.71-$5.81 per share.\nRevenues are projected between $9.10 billion and $9.25 billion, suggesting an operational growth of 9-11%. Total revenues were previously projected between $9.05 billion and $9.2 billion.\nHow Have Estimates Been Moving Since Then?\nIn the past month, investors have witnessed a downward trend in fresh estimates.\nVGM Scores\nAt this time, Zoetis has a subpar Growth Score of D, a grade with the same score on the momentum front. Following the exact same course, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.\nOverall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.\nOutlook\nEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Zoetis has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.\nPerformance of an Industry Player\nZoetis is part of the Zacks Medical - Drugs industry. Over the past month, Ionis Pharmaceuticals (IONS), a stock from the same industry, has gained 1.8%. The company reported its results for the quarter ended June 2024 more than a month ago.\nIonis Pharmaceuticals reported revenues of $225 million in the last reported quarter, representing a year-over-year change of +19.7%. EPS of -$0.45 for the same period compares with -$0.60 a year ago.\nFor the current quarter, Ionis Pharmaceuticals is expected to post a loss of $1.17 per share, indicating a change of -13.6% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.1% over the last 30 days.\nThe overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Ionis Pharmaceuticals. Also, the stock has a VGM Score of F.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nZoetis Inc. (ZTS) : Free Stock Analysis Report\nIonis Pharmaceuticals, Inc. (IONS) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2465834520"}